Orchestra BioMed Holdings Reports Increased Loss in Q3
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Source: NASDAQ.COM
Third-Quarter Financial Performance: Orchestra BioMed Holdings, Inc. reported a net loss of $20.8 million or $0.40 per share for the third quarter, an increase from a net loss of $15.4 million or $0.41 per share in the same quarter of 2024.
Revenue Comparison: The company's revenue for the third quarter was $861 thousand, down from $987 thousand in the third quarter of 2024.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on OBIO
Wall Street analysts forecast OBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OBIO is 14.25 USD with a low forecast of 10.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.930
Low
10.00
Averages
14.25
High
20.00
Current: 3.930
Low
10.00
Averages
14.25
High
20.00
About OBIO
Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Orchestra BioMed and Medtronic Collaborate on AVIM Therapy Development for Hypertension
- Strategic Collaboration: Orchestra BioMed's partnership with Medtronic aims to develop AVIM Therapy, which has received FDA Breakthrough Device Designation, potentially offering a new treatment option for 7.7 million U.S. patients with uncontrolled hypertension, significantly enhancing patient quality of life.
- Clinical Trial Progress: The MODERATO II study demonstrated that AVIM Therapy reduced 24-hour ambulatory systolic blood pressure by an average of 8.1 mmHg over six months, indicating its effectiveness in hypertension management and potentially opening up multi-billion-dollar market opportunities for the company.
- Innovative Product: The Virtue® Sirolimus AngioInfusion™ Balloon, as the first non-coated drug delivery system, has also received FDA Breakthrough Device Designation, aimed at treating coronary in-stent restenosis, which is expected to transform the treatment landscape for cardiovascular diseases.
- Market Potential: The successful development of AVIM Therapy and Virtue SAB will position Orchestra BioMed prominently in the global cardiovascular market, particularly in hypertension and atherosclerosis, driving long-term growth for the company.
Continue Reading
Orchestra BioMed and Medtronic Collaborate on AVIM Therapy Development
- Strategic Collaboration Highlight: Orchestra BioMed's partnership with Medtronic aims to develop AVIM Therapy, which has received FDA Breakthrough Device Designation, potentially offering new treatment options for 7.7 million U.S. patients with uncontrolled hypertension, significantly enhancing patient quality of life.
- Clinical Trial Progress: In the MODERATO II trial, AVIM Therapy demonstrated an average reduction of 8.1 mmHg in 24-hour ambulatory systolic blood pressure over six months, showcasing its efficacy in hypertension management and potentially transforming treatment paradigms.
- Innovative Product Introduction: Virtue SAB, as the first non-coated drug delivery system, has also received FDA Breakthrough Device Designation for treating coronary in-stent restenosis, highlighting its potential in cardiovascular disease treatment and opening new market opportunities.
- Industry Impact: The three presentations at the Innovation in Cardiology Intervention meeting in Israel underscore Orchestra BioMed's leadership in biomedical innovation, further solidifying its strategic collaboration with Medtronic and advancing the commercialization of high-impact technologies.
Continue Reading